BEAT-SHOCK Registry (BEAT-SHOCK)

BEAT-SHOCK (Basel Evaluation of Acute Therapy in Cardiogenic SHOCK) Registry

This regulation defines the purpose, the operational processes, and the organization of the registry BEAT-SHOCK (Basel Evaluation of Acute Therapy in cardiogenic SHOCK). It describes the requirements for collecting, storing, processing, managing and sharing health-related registry data.

Study Overview

• Status: Recruiting
• Conditions: Acute Decompensated Heart Failure; Cardiogenic Shock; Myocardial Infarction (MI); Fulminant Myocarditis; Severe Valvular Disease; Post-cardiotomy; Perioperative Cardiogenic Shock
• Intervention / Treatment: Other: no internvention

• Study Type: Observational
• Enrollment (Estimated): 8000

Contacts and Locations

• Study Contact: Name: Jasper Boeddinghaus, PD Dr. med.; Phone Number: 0041613287897; Email: jasper.boeddinghaus@usb.ch
• Study Contact Backup: Name: Gregor Leibundgut, Prof. Dr.; Phone Number: 0041613287897; Email: gregor.leibundgut@usb.ch

Study Locations

• Switzerland
  • Canton of Basel-City
    • Basel, Canton of Basel-City, Switzerland, 4031
      • Recruiting
      • University Hospital Basel
      • Principal Investigator: Jasper Boeddinghaus, PD Dr. med.
      • Contact: Jasper Boeddinghaus, PD Dr. med.; Phone Number: 0041613287897; Email: jasper.boeddinghaus@usb.ch
      • Contact: Gregor Leibundgut, Prof. Dr. med.; Email: gregor.leibundgut@usb.ch
      • Principal Investigator: Gregor Leibundgut, Prof. Dr. med.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients who are treated at the University Hospital Basel and are diagnosed with cardiogenic shock, irrespective of underlying etiology or therapeutic strategy. The registry includes a wide range of cardiogenic shock etiologies, including:

• Myocardial infarction (MI)
• Fulminant myocarditis
• Acute decompensated heart failure
• Severe valvular disease
• Post-cardiotomy or perioperative cardiogenic shock

Description

• Patients admitted with cardiogenic shock to the University hospital Basel (diagnosis at the time of admission) or development of cardiogenic shock during the hospital stay
• Age ≥18 years
• Provision of written ICF
• Clinical diagnosis of cardiogenic shock.
• impaired organ perfusion due to primary cardiac dysfunction,
• persistent systolic blood pressure (SBP) <90 mmHg for ≥30 minutes, or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain adequate perfusion and
• evidence of systemic hypoperfusion with arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l and ≥1 of the following:
• Cold or clammy extremities
• Altered mental status
• Reduced urine output
• Signs of volume overload or congestion (on clinical exam, imaging, or invasive monitoring)
• Patients with normotensive cardiogenic shock (SBP ≥90 mmHg without vasopressors or MCS) may also be included if clear signs of hypoperfusion (arterial lactate ≥2 mmol/L or venous lactate ≥3 mmol/l) and cardiac dysfunction are present and alternative causes are excluded

Exclusion criteria:

• Age <18 years
• Refusal to provide informed consent by the patient or their legally authorized representative

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
In-Hospital all-cause mortality occurring before discharge from the participating study centre	In-hospital all-cause mortality is defined as death occurring before discharge from the participating study centre. Deaths occurring after transfer to an external hospital are not counted as in-hospital deaths, but are captured through follow-up for 30-day and 90-day mortality.	10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
30-day and 90-day all-cause Mortality	30-day and 90-day all-cause mortality occuring after discharge from the participating study centre.	30, 90 days
Need for organ support at any time during hospitalization	The need for organ support at any time during hospitalization (including renal replacement therapy, mechanical circulation support irrespective of type, and vasoactive or inotropic therapy)	30, 60, 360 days
Acute kidney injury (AKI) within 36 hours after index diagnosis of cardiogenic shock/index presentation	Occurence of AKI (defined as an increase in serum creatinine of at least 26 µmol/L (0.3 mg/dL)	Within 36 hours after index diagnosis of cardiogenic shock/ index presentation.

Collaborators and Investigators

• Sponsor: University Hospital, Basel, Switzerland

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2025
• Primary Completion (Estimated): October 1, 2035
• Study Completion (Estimated): October 1, 2035

Study Registration Dates

• First Submitted: May 29, 2026
• First Submitted That Met QC Criteria: June 8, 2026
• First Posted (Actual): June 11, 2026

Study Record Updates

• Last Update Posted (Actual): June 11, 2026
• Last Update Submitted That Met QC Criteria: June 8, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: Acute decompensated heart failure; cardiogenic shock; Myocardial infarction (MI); Fulminant myocarditis; Severe valvular disease; Post-cardiotomy or perioperative cardiogenic shock; wide range of cardiogenic shock etiologies
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Infarction; Necrosis; Myocardial Ischemia; Ischemia; Shock; Pathological Conditions, Signs and Symptoms; Shock, Cardiogenic; Myocardial Infarction
• Other Study ID Numbers: BEAT SHOCK

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: Not necessary, only data registry.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No